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Summary
 
We report that chlamydiae, which are obligate intracellular bacterial pathogens, can inhibit in-
terferon (IFN)-
 
g
 
–inducible major histocompatibility complex (MHC) class II expression.
However, the IFN-
 
g
 
–induced IFN regulatory factor-1 (IRF-1) and intercellular adhesion mol-
ecule 1 (ICAM-1) expression is not affected, suggesting that chlamydia may selectively target
the IFN-
 
g
 
 signaling pathways required for MHC class II expression. Chlamydial inhibition of
MHC class II expression is correlated with degradation of upstream stimulatory factor (USF)-1,
a constitutively and ubiquitously expressed transcription factor required for IFN-
 
g
 
 induction of
class II transactivator (CIITA) but not of IRF-1 and ICAM-1. CIITA is an obligate mediator
of IFN-
 
g
 
–inducible MHC class II expression. Thus, diminished CIITA expression as a result of
USF-1 degradation may account for the suppression of the IFN-
 
g
 
–inducible MHC class II in
chlamydia-infected cells. These results reveal a novel immune evasion strategy used by the in-
tracellular bacterial pathogen chlamydia that improves our understanding of the molecular basis
of pathogenesis.
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T
 
lymphocyte recognition of MHC–peptide complexes
on target cells is essential for mounting an antigen-spe-
cific immune attack (1), which may in turn select pathogens
able to evade immune recognition by suppressing MHC ex-
pression on the infected cells (2). Many intracellular patho-
gens have evolved various strategies for inhibiting MHC
molecule expression on infected cells to avoid T lympho-
cyte recognition. For example, to escape CD8
 
1
 
 T cell rec-
ognition, a variety of viruses are found to suppress surface
expression of MHC class I on the infected cells (3–12). To
escape CD4
 
1
 
 T cell recognition, pathogens may need to
inhibit the IFN-
 
g
 
–inducible MHC class II expression. This
is because IFN-
 
g
 
 induction is often required to upregulate
MHC class II molecules on nonprofessional APCs, such as
epithelial cells, that are usually the natural targets of intra-
cellular pathogens. It has been demonstrated that IFN-
 
g
 
–
inducible MHC class II expression is inhibited in cells in-
fected with various intracellular pathogens (13–18), which
suggests that suppression of IFN-
 
g
 
–inducible MHC class II
may represent an immune evasion strategy used by intracel-
lular pathogens.
Chlamydia is an obligate intracellular bacterial pathogen
(19) and the causative agent of many important human dis-
eases (20, 21). Although specific immune responses are
provoked after a chlamydial infection, persistent infection
often occurs (22, 23). We have recently demonstrated that
chlamydia possesses a strong antiapoptotic activity (24),
which may allow chlamydiae to escape CD8
 
1
 
 T cell attack.
However, CD4
 
1
 
 T cell–mediated immunity also plays very
important roles in controlling many intracellular pathogen
infections (25, 26). As viruses that suppress IFN-
 
g
 
–induc-
ible MHC class II expression on the infected cells can
evade CD4
 
1
 
 T cell recognition (16), we hypothesize that
chlamydia may have also evolved strategies for inhibiting
IFN-
 
g
 
 induction of MHC class II, which may partially
contribute to the persistent infection. To test this hypothe-
sis, we evaluated the effect of chlamydial infection on IFN-
 
g
 
–
inducible MHC class II antigen expression. We have found
 
that chlamydial infection can indeed suppress
 
 
 
IFN-
 
g
 
–
inducible MHC class II expression by selective disruption
 
of IFN-
 
g
 
 signaling pathways.
 
 
 
We further demonstrated
that a chlamydia-dependent proteasome-like activity is re-
sponsible for the chlamydial inhibitory effect. These obser-
vations reveal a novel immune evasion strategy used by the
intracellular bacterial pathogen chlamydia.
 
Materials and Methods
 
Chlamydial Infection and IFN-
 
g
 
 Stimulation.
 
The following
human cell lines were used: MCF-7 (a mammary epithelium line, 
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provided by Dr. Arnold Greenberg of the Manitoba Cancer
Foundation); MRC-5 (fibroblast; American Type Culture Col-
lection [ATCC]); 2C4 (fibroblast; provided by Dr. George Stark
of the Cleveland Clinic Foundation); and HeLa (cervical epithe-
lium; ATCC). Cells were infected with 
 
Chlamydia trachomatis
 
LGV2 strain at a multiplicity of infection (MOI)
 
1
 
 of 5 or as indi-
cated and for 24 h or as indicated in individual experiments (24).
Cells with or without infection were stimulated with human
IFN-
 
g
 
 (PharMingen) at 200 U/ml or as indicated for another 10 h
(for reverse transcriptase [RT]-PCR analysis) or 20–24 h (for flow
cytometry and Western blot analysis).
 
Flow Cytometry.
 
Cell samples were stained with mouse anti–
HLA-DR
 
a
 
 (L243; ATCC), mouse anti–human intercellular ad-
hesion molecule (ICAM)-1 (HA58; PharMingen), or normal
mouse IgG (Zymed Labs., Inc.). Primary antibody binding was
detected using goat anti–mouse IgG conjugated with FITC (Cal-
tag Labs.) and analyzed with a FACSCalibur™ equipped with
CellQuest software (Becton Dickinson). Dead cells were ex-
cluded by propidium iodine staining.
 
Western Blot Assay.
 
Western blot assay was carried out as we
previously described (24). Rabbit antibodies were used to detect
IFN-
 
g
 
R (SC-700; Santa Cruz Biotechnology), tyrosine-phos-
phorylated signal transducers and activators of transcription
(STAT)1
 
a
 
 (9171S; New England Biolabs, Inc.), IFN regulatory
factor (IRF)-1 (SC-497), upstream stimulatory factor (USF)-1
(SC-229) and USF-2 (SC-862; all from Santa Cruz Biotechnol-
ogy). Mouse antibodies were used to detect Janus tyrosine kinase
(JAK)-1 (J24320; Transduction Labs.) and STAT1
 
a
 
 (SC-464; Santa
Cruz Biotechnology), HLA-DR
 
a
 
 (DA6.147; provided by Dr.
Peter Cresswell, Yale University; reference 27), and a chlamydial
major outer membrane protein (MOMP; clone MC22, our un-
published data). Primary antibody binding was detected with
horseradish peroxidase–conjugated goat anti–mouse IgG or –rabbit
IgG, depending on the source of the primary antibodies, and vi-
sualized using an ECL kit (Amersham Corp.).
 
RT-PCR Assay.
 
Cell samples were collected for RNA ex-
traction using the Rneasy Mini Kit from QIAGEN, Inc. 2 
 
m
 
g of
total RNA was used for each cDNA synthesis with random
primers and the 1
 
st
 
 Strand cDNA synthesis kit from Boehringer
Mannheim. Aliquots of the cDNA samples were used as a tem-
plate for amplifying specific gene fragments by PCR reactions
(28, 29). The primers used for amplification of DR
 
a
 
 (18), DM
 
a
 
(29), invariant chain p41 (IP41) (29), and IRF-1 (18) were previ-
ously described. The other primers used in this study were: for
class II transactivator (CIITA) amplification, 5
 
9
 
-GACACGGTG-
GCGCTGTGGGAGTC-3
 
9
 
 (forward) and 5
 
9
 
-GGCAGCCGT-
GAACTTGTTGTACTGG-3
 
9
 
 (reverse); for USF-1 amplification,
5
 
9
 
-TGGCACTGGTCAATTCTTTGTG (forward) and 5
 
9
 
-GTT-
GCTGTCATTCTTGATGAC (reverse); for STAT1 amplifica-
tion, 5
 
9
 
-TAGAGTTGCTGAATGTCACTG-3
 
9
 
 (forward) and
5
 
9
 
-GGAGTGAAGCTCTTCAGTAAC-3
 
9
 
 (reverse); for indole-
amine  2,3-dioxygenase (IDO) gene amplification, 5
 
9
 
-ATGCAT-
CACCATGGCATA-3
 
9
 
 (forward) and 5
 
9
 
-GCTTCCCGCAG-
GCCAGCATCA-3
 
9
 
 (reverse); and for 
 
b
 
-actin amplification,
5
 
9
 
-GTGGGGCGCCCCAGGCACCA-3
 
9
 
 (forward) and 5
 
9
 
-CTC-
CTTAATGTCACGCACGATTTC-3
 
9
 
 (reverse). 
 
b
 
-actin mRNA
detection was used as an internal control for the amount of
cDNA synthesized. To ensure the specificity of the mRNA de-
tection, all primers were designed to cover at least two exons, and
parallel samples without RT were run as negative controls. The
amplified DNA products were run on an agarose gel and visual-
ized with ethidium bromide staining.
 
Results
 
Chlamydial Infection Inhibits IFN-
 
g
 
–inducible MHC Class
II Gene Expression.
 
To investigate whether chlamydia
possesses the ability to evade the IFN-
 
g
 
–induced immune rec-
ognition mechanism, we evaluated IFN-
 
g
 
–inducible MHC
class II antigen expression in cells with or without chlamydial
infection. IFN-
 
g
 
 significantly upregulated HLA-DR surface
expression on uninfected cells, whereas the chlamydia-
infected cells displayed a minimal level of DR, regardless of
IFN-
 
g
 
 exposure (Fig. 1 A). However, chlamydial infection
did not affect the IFN-
 
g
 
–induced ICAM-1 surface expres-
sion (Fig. 1 A). These observations suggest that chlamydia
selectively inhibits IFN-
 
g
 
–inducible DR expression rather
than preventing all IFN-
 
g
 
 dependent signaling or generally
suppressing surface protein expression. Furthermore, the to-
tal cellular protein level of IFN-
 
g
 
–induced HLA-DR
 
a
 
was also significantly diminished in chlamydia-infected cells
Figure 1. Chlamydial infection selectively inhibits IFN-g–inducible
MHC class II expression. MCF-7 cells with or without chlamydial infec-
tion were stimulated with IFN-g and collected for flow cytometry (A),
Western blot (B), and RT-PCR (C) analysis. (A) Chlamydial infection
prevents IFN-g–inducible HLA-DR but not ICAM-1 surface expression.
(B) Chlamydial infection suppresses the total cellular protein level of
IFN-g–inducible HLA-DRa in various human cell lines. MRC-5, 2C4,
and HeLa cells were stimulated with IFN-g at 400 U/ml. HLA-DRa
was detected in a Western blot assay. (C) Chlamydial infection inhibits
HLA-DRa, DMa, and Ip41 mRNA expression. Gene-specific primers
were used to amplify random primer–directed cDNA templates in an
RT-PCR reaction as described in Materials and Methods.
 
1
 
Abbreviations used in this paper:
 
 CIITA, class II transactivator; IDO, in-
doleamine 2,3-dioxygenase; IRF, interferon regulatory factor; JAK, Janus
tyrosine kinase; MOI, multiplicity of infection; MOMP, major outer
membrane protein; RT, reverse transcriptase; STAT, signal transducers
and activators of transcription; USF, upstream stimulatory factor. 
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as compared with uninfected cells (Fig. 1 B), suggesting that
the suppression of surface expression of HLA-DR was not
due to an alteration in intracellular trafficking. The chlamy-
dial inhibition of IFN-
 
g
 
–inducible HLA-DR
 
a
 
 was repro-
duced in many other human cell lines, including HeLa,
MRC-5, and 2C4 (Fig. 1 B), demonstrating that the inhibi-
tory effect is not a cell line–specific phenomenon. To deter-
mine whether the chlamydial inhibition of HLA-DR ex-
pression occurs at the transcription or translation level, MHC
class II mRNA levels were evaluated by semiquantitative
RT-PCR. IFN-
 
g
 
 dramatically induced the expression of
DR
 
a
 
, DM
 
a
 
, and Ip41 mRNA in the uninfected but not the
infected cells (Fig. 1 C), suggesting that chlamydial inhibition
of MHC class II occurred at the transcription level. Because
the genes encoding the MHC class II presentation–related
molecules DR
 
a
 
, DM
 
a
 
, and Ip41 share similar promoter
structures and CIITA is a master regulator for the expression
of these genes (30), we hypothesize that chlamydia may in-
hibit CIITA function or CIITA gene expression.
 
IFN-
 
g
 
–inducible CIITA Expression Is Inhibited in Chlamy-
dia-infected Cells.
 
Although CIITA is constitutively ex-
pressed in professional APCs, such as dendritic cells and B
cells, IFN-
 
g
 
 stimulation is often required for the expression
of CIITA in nonprofessional APCs, such as epithelial cells
(31). CIITA mRNA expression was induced by IFN-
 
g
 
 in
uninfected MCF-7 cells (Fig. 2 A). However, CIITA
mRNA expression was significantly lower in chlamydia-
infected and IFN-
 
g
 
–treated cells (Fig. 2 A), in accord with
chlamydial inhibition of MHC class II gene expression. To
investigate how CIITA gene expression was inhibited, we
measured mRNA levels for three transcription factors,
USF-1, STAT1, and IRF-1, all of which are required for
IFN-
 
g
 
–inducible transcription of the CIITA gene (32).
Both USF-1 and STAT1 mRNAs were constitutively ex-
pressed, and IRF-1 mRNA was induced by IFN-
 
g
 
 in
MCF-7 cells regardless of chlamydial infection (Fig. 2 A),
suggesting that chlamydial infection did not affect tran-
scription of the genes for these nuclear factors. Because the
three transcription factors are considered to be sufficient
and necessary for the IFN-
 
g
 
 induction of CIITA (32), we
evaluated the protein levels of these transcription factors as
well as upstream molecules in the IFN-
 
g
 
 signaling path-
way. We found that IFN-
 
g
 
R, JAK-1, and STAT1 protein
levels were not altered by chlamydial infection (Fig. 2 B).
Chlamydia did not affect IFN-
 
g
 
–induced STAT1 tyrosine
phosphorylation (Fig. 2 B). Furthermore, IFN-
 
g
 
 induced
both IRF-1 and ICAM-1 expression in chlamydia-infected
cells (Figs. 1 A and 2 B). As STAT1 is required for the ex-
pression of both IRF-1 and ICAM-1 genes (32, 33), we
conclude that STAT1 is transcriptionally functional in
chlamydia-infected cells. The IFN-
 
g
 
–induced IRF-1 in
chlamydia-infected cells may also be transcriptionally func-
tional, as we found that IFN-
 
g
 
 induced expression of IDO
gene in chlamydia-infected cells (data not shown), and it is
known that IRF-1 is required for IFN-
 
g
 
 induction of IDO
(34). Therefore, the failure of the IFN-
 
g
 
–inducible CIITA
expression in chlamydia-infected cells is likely due to the
deficiency in USF-1. We found that the USF-1 protein
was not detectable in chlamydia-infected cells (Fig. 2 B),
despite normal USF-1 mRNA expression (Fig. 2 A). We
next determined the cause of the USF-1 protein loss.
 
USF-1 Is Degraded by a Proteasome-like Activity in Chlamy-
dia-infected Cells.
 
Because USF-1 mRNA is expressed in
chlamydia-infected cells with or without IFN-
 
g
 
 stimula-
tion, the lack of USF-1 protein may be due to either the
inhibition of translation of USF-1 mRNA or the acceler-
ated degradation of USF-1 protein. We tested the protein
degradation hypothesis by using protease inhibitors. We
found that the proteasome inhibitor lactacystin prevented
USF-1 protein degradation in chlamydia-infected cells
(Fig. 2 C). Furthermore, the lactacystin treatment also pre-
served the IFN-
 
g
 
–inducible HLA-DR expression in chlamy-
Figure 2. Chlamydial infection disrupts IFN-g intracellular signaling path-
ways. (A) Chlamydial infection suppresses both HLA-DRa and CIITA but not
IRF-1, STAT1a, or USF-1 mRNA expression in MCF-7 cells. The mRNA
levels were analyzed by RT-PCR as described in Materials and Methods. (B)
USF-1 protein is not detected in chlamydia-infected MCF-7 cells. The protein levels of IFN-gR, JAK-1, STAT1a, tyrosine-phosphorylated STAT1a,
IRF-1, and USF-1 were detected using a Western blot assay. (C) Lactacystin prevents USF-1 degradation and preserves HLA-DRa expression in
chlamydia-infected MCF-7 cells. 10 h before IFN-g stimulation, a chlamydia-infected cell sample was treated with lactacystin (Calbiochem) at a final
concentration of 75 mM or with an equivalent amount of solvent DMSO and kept in culture during IFN-g stimulation. HLA-DRa and USF-1 were de-
tected in a Western blot assay. ns, nonspecific binding.1934 Chlamydial Inhibition of MHC Class II
dia-infected cells (Fig. 2 C). These observations not only
demonstrate that a proteasome-like activity is responsible
for the loss of USF-1 protein in chlamydia-infected cells
but also suggest that USF-1 degradation may be responsible
for the chlamydial suppression of MHC class II expression.
Both USF-1 Degradation and MHC Class II Suppression in
Chlamydia-infected Cells Are Dependent on Chlamydial but not
Host Protein Synthesis. To examine whether the USF-1
protein degradation in chlamydia-infected cells is depen-
dent on chlamydial growth and protein synthesis, we first
evaluated the relationship between the chlamydial infection
dose and USF-1 degradation. As MOI (ratio of number of
organisms versus number of host cells) increased, more
chlamydial protein was produced and less USF-1 protein
was detected (Fig. 3 A). This effect was selective, as USF-2
was not degraded, regardless of the infection dose (Fig. 3 A).
The time course relationship between chlamydial growth
and USF-1 degradation was also analyzed (Fig. 3 B). Al-
though the STAT1 protein level was not affected by chlamy-
dial infection at any time points examined, significant USF-1
degradation was detected 17 h after chlamydial infection,
when chlamydial protein synthesis approached its maxi-
mum (Fig. 3 B). The role of chlamydial and host protein
synthesis in USF-1 degradation was examined using antibio-
tics specifically inhibiting either prokaryotic or eukaryotic
protein synthesis. We found that both rifampin (inhibiting
prokaryotic transcription) and chloramphenicol (inhibiting
prokaryotic translation) blocked chlamydial protein synthe-
sis (Fig. 3 C). More importantly, these antibiotics also pre-
vented USF-1 degradation and preserved HLA-DRa ex-
pression in chlamydia-infected cells (Fig. 3 C). However,
treatment with penicillin failed to prevent USF-1 degrada-
tion and preserve HLA-DRa expression (Fig. 3 C). Peni-
cillin only blocks chlamydial particle assembly without in-
hibiting chlamydial protein synthesis (35). Penicillin did not
alter the constitutively expressed USF-1 protein level and
IFN-g–inducible HLA-DRa expression in uninfected cells
(Fig. 3 C). Together, these observations demonstrate that
chlamydial protein synthesis, but not particle assembly, is
necessary for chlamydia-induced degradation of USF-1
protein and suppression of HLA-DRa expression. Finally,
cycloheximide treatment did not affect the chlamydia-
induced degradation of USF-1 (Fig. 3 C). Because cyclohex-
imide did not affect chlamydial protein synthesis but com-
pletely inhibited new protein synthesis by the host cell, for
example, production of IFN-g–induced HLA-DRa (Fig.
3 C), we conclude that newly synthesized host proteins are
not required for chlamydia-induced degradation of USF-1.
Discussion
We have demonstrated that the obligate intracellular
bacterial pathogen chlamydia can inhibit IFN-g–inducible
MHC class II expression. This inhibitory effect has also
been found with other intracellular pathogens, including
leishmania (13), listeria (14), cowdria (15), and cytomega-
lovirus (16–18). CD41 T cell–mediated immunity plays an
important role in host defense against various intracellular
infections (36–38). Recognition of the infected cells by
CD41 T cells often requires IFN-g induction of MHC
class II expression, because many pathogen-targeted cells,
such as epithelial cells, are generally MHC class II–nega-
tive. Suppression of IFN-g–inducible MHC class II expres-
sion may represent an efficient immune evasion strategy
used by intracellular pathogens to escape host defenses.
Thus, chlamydial inhibition of IFN-g–inducible MHC
class II may contribute to the persistent infection caused by
chlamydia in humans (22).
It has been demonstrated that cytomegalovirus can pre-
vent IFN-g–inducible class II expression in infected cells
by both IFN-b–mediated inhibition (17, 39) and disrup-
tion of IFN-g intracellular signaling pathways (16, 18).
However, mechanisms of IFN-g–inducible MHC class II
inhibition by many other intracellular pathogens are still
not clear (13–15). It was recently proposed that chlamydia
Figure 3. Chlamydial protein synthesis is required for both USF-1
degradation and inhibition of HLA-DRa expression. (A) Correlation be-
tween infection dose and USF-1 degradation. 24 h after chlamydial infec-
tion at various MOI, MCF-7 cells were analyzed for chlamydial MOMP
and host USF-1 and USF-2 protein levels in a Western blot assay. As the
USF-2 protein level was not altered by chlamydial infection, it served as
an internal control. (B) Time course relationship between chlamydial
growth and USF-1 degradation. At various time points after infection,
MCF-7 cells were lysed for the detection of USF-1, STAT1a, and
MOMP in a Western blot assay. (C) Inhibition of chlamydial but not host
protein synthesis prevents USF-1 degradation and preserves HLA-DRa
expression. Rifampin (RF; final concentration, 0.1 mg/ml), chloram-
phenicol (CH; 60 mg/ml), and penicillin (PG; 100 mg/ml) were added at
the beginning of chlamydial infection and maintained throughout the
culture. Cycloheximide (CY; 10 mg/ml) was added to the culture 10 h
before IFN-g treatment and maintained during the IFN-g stimulation.
The MCF-7 cells were analyzed for protein levels of HLA-DRa, USF-1,
USF-2, and chlamydial MOMP in a Western blot assay.1935 Zhong et al.
may suppress IFN-g–inducible MHC class II expression by
stimulating host cells to release IFN-b (40). Here we show
that the intracellular bacterial pathogen chlamydia has
evolved a more specific mechanism for disrupting IFN-g
signaling pathways and inhibiting MHC class II expression.
Chlamydia degrades USF-1, a downstream transcription
factor required for IFN-g–inducible MHC class II but not
IRF-1 and ICAM-1 expression (Fig. 4). USF-1 degrada-
tion may represent an efficient means of interrupting IFN-g–
inducible MHC class II expression by chlamydia. Although
the constitutively and ubiquitously expressed USF-1 is a
member of the basic helix-loop-helix family consisting of
multiple transcription factors, including Myc and USF-2,
only USF-1 is both necessary and sufficient for binding to
the E box within the CIITA promoter IV and cooperating
with STAT1 and IRF-1 for promoting transcription of
CIITA (32). Therefore, the constitutively and ubiquitously
expressed USF-1 may serve as a convenient and efficient
target for chlamydia-induced degradation. The correlation
between the degradation of USF-1 and the suppression of
IFN-g–inducible MHC class II further confirms that USF-1
plays a critical role in IFN-g induction of MHC class II
(32). Besides its involvement in MHC class II expression,
USF-1 also participates in many other cellular activities, in-
cluding promoting the transcription of fatty acid synthase
in response to insulin regulation (41), interfering with Ras
transformation (42), and transactivating the promoter of the
p53 tumor suppressor gene (43). Depletion of USF-1 may
cause inhibition of host cell lipid biosynthesis and promo-
tion of host cell survival, both of which are likely beneficial
to the intracellular chlamydia organisms.
Proteolysis is an important aspect of normal cellular
physiology (44–46). Many viruses can take advantage of
host proteolysis for the purposes of evading host defenses
(2, 47). For example, human cytomegalovirus infection can
induce degradation of JAK-1, a critical upstream kinase re-
quired for IFN-g JAK/STAT signaling pathways, to sup-
press IFN-g–inducible MHC class II on the infected cells
(18). Furthermore, the cytomegalovirus-induced degrada-
tion can be inhibited by the proteasome inhibitor Z-L3VS
(18, 48), suggesting that cytomegalovirus may be able to
manipulate host proteasome activity. Because USF-1 deg-
radation by chlamydia is inhibitable by lactacystin and lacta-
cystin is a potent proteasome inhibitor (48, 49), we propose
that chlamydia may also produce a factor(s) for manipulating
host proteasomes. Efforts to identify the chlamydial fac-
tor(s) are underway.
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